| Scott R Anagnoste, MD | |
|
6333 N Federal Hwy, Suite 300, Ft Lauderdale, FL 33308-1907 | |
| (954) 776-6880 | |
| (954) 229-3100 |
| Full Name | Scott R Anagnoste |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 30 Years |
| Location | 6333 N Federal Hwy, Ft Lauderdale, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487652566 | NPI | - | NPPES |
| 256556100 | Medicaid | FL | |
| 46744 | Other | FL | BCBSFL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | ME78161 (Florida) | Secondary |
| 207WX0107X | Ophthalmology - Retina Specialist | ME78161 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Broward Health Imperial Point | Fort lauderdale, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Retina Vitreous Consultants | 4082610019 | 34 |
News Archive
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
"We're trying to get to the underlying state of the brain that leads to these seizures," said Mark Kramer, a Ph.D. student in UC Berkeley's Applied Science and Technology Program and lead author of the paper. "Our hope is that the model can highlight potential areas where a seizure can be stopped."
Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use in patients with primary immunodeficiency (PI).
In the first study to investigate driving as it relates to teens with a high-functioning autism disorder (HFASD), child development and teen driving experts at The Children's Hospital of Philadelphia's Center for Child Injury Prevention Studies found that two-thirds of teenagers with a high-functioning autism spectrum disorder (HFASD) who are of legal driving age in their state are currently driving or plan to drive.
› Verified 5 days ago
| Entity Name | Retina Vitreous Consultants |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699773796 PECOS PAC ID: 4082610019 Enrollment ID: O20061013000180 |
News Archive
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
"We're trying to get to the underlying state of the brain that leads to these seizures," said Mark Kramer, a Ph.D. student in UC Berkeley's Applied Science and Technology Program and lead author of the paper. "Our hope is that the model can highlight potential areas where a seizure can be stopped."
Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use in patients with primary immunodeficiency (PI).
In the first study to investigate driving as it relates to teens with a high-functioning autism disorder (HFASD), child development and teen driving experts at The Children's Hospital of Philadelphia's Center for Child Injury Prevention Studies found that two-thirds of teenagers with a high-functioning autism spectrum disorder (HFASD) who are of legal driving age in their state are currently driving or plan to drive.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott R Anagnoste, MD 6333 N Federal Hwy, Suite 300, Ft Lauderdale, FL 33308-1907 Ph: (954) 776-6880 | Scott R Anagnoste, MD 6333 N Federal Hwy, Suite 300, Ft Lauderdale, FL 33308-1907 Ph: (954) 776-6880 |
News Archive
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
"We're trying to get to the underlying state of the brain that leads to these seizures," said Mark Kramer, a Ph.D. student in UC Berkeley's Applied Science and Technology Program and lead author of the paper. "Our hope is that the model can highlight potential areas where a seizure can be stopped."
Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use in patients with primary immunodeficiency (PI).
In the first study to investigate driving as it relates to teens with a high-functioning autism disorder (HFASD), child development and teen driving experts at The Children's Hospital of Philadelphia's Center for Child Injury Prevention Studies found that two-thirds of teenagers with a high-functioning autism spectrum disorder (HFASD) who are of legal driving age in their state are currently driving or plan to drive.
› Verified 5 days ago
Dr. Eric Charles Gechter, MD Ophthalmology Medicare: May Accept Medicare Assignments Practice Location: 2900 W Cypress Creek Rd, Suite 1, Ft Lauderdale, FL 33309 Phone: 954-977-0192 Fax: 954-977-0197 | |
Daniel Gologorsky, MD, MBA Ophthalmology Medicare: May Accept Medicare Assignments Practice Location: 1625 Se 3rd Ave Ste 501, Ft Lauderdale, FL 33316 Phone: 954-468-8072 Fax: 954-468-8087 | |
Patrick E Rubsamen, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6333 N Federal Hwy, Suite 300, Ft Lauderdale, FL 33308 Phone: 954-776-6880 Fax: 954-229-3100 | |
Dr. Krista D Rosenberg, Ophthalmology Medicare: Medicare Enrolled Practice Location: 6333 N Federal Hwy, Suite 300, Ft Lauderdale, FL 33308 Phone: 954-776-6880 Fax: 954-229-3100 | |
George A Fournier, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2466 E Commercial Blvd, Ft Lauderdale, FL 33308 Phone: 954-492-1177 Fax: 954-492-0352 | |
Dr. Robert Lee Kramm Iii, MD, MSE Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1281 S Ocean Dr, Ft Lauderdale, FL 33316 Phone: 720-252-8488 | |
John F Sciarrino, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5601 N. Dixie Hwy, Ste 115, Ft Lauderdale, FL 33334 Phone: 954-771-4271 Fax: 954-776-5959 |